LASOFOXIFENE HCL
- CAS No.
- 190791-29-8
- Chemical Name:
- LASOFOXIFENE HCL
- Synonyms
- Lasofoxifene tartrate;Oporia;Cb 336156eb;Unii-85X09V2gso;LASOFOXIFENE HCL;CP-336,156 tartrate;(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1)
- CBNumber:
- CB91516053
- Molecular Formula:
- C32H37NO8
- Molecular Weight:
- 563.65
- MDL Number:
- MFCD13185249
- MOL File:
- 190791-29-8.mol
- MSDS File:
- SDS
| Melting point | 185 °C(dec.) |
|---|---|
| storage temp. | 2-8°C |
| solubility | DMSO: soluble10mg/mL, clear |
| form | powder |
| color | white to beige |
| FDA UNII | 85X09V2GSO |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319 | |||||||||
| Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 | |||||||||
| WGK Germany | 3 | |||||||||
| HS Code | 2933.99.7500 | |||||||||
| NFPA 704 |
|
LASOFOXIFENE HCL price More Price(27)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1026 | Lasofoxifene tartrate ≥98% (HPLC) | 190791-29-8 | 10mg | $48 | 2024-03-01 | Buy |
| Sigma-Aldrich | SML1026 | Lasofoxifene tartrate ≥98% (HPLC) | 190791-29-8 | 50mg | $476 | 2024-03-01 | Buy |
| TCI Chemical | L0336 | Lasofoxifene Tartrate | 190791-29-8 | 10MG | $87 | 2024-03-01 | Buy |
| TCI Chemical | L0336 | Lasofoxifene Tartrate | 190791-29-8 | 50MG | $264 | 2024-03-01 | Buy |
| Cayman Chemical | 17646 | Lasofoxifene (tartrate) ≥98% | 190791-29-8 | 5mg | $49 | 2024-03-01 | Buy |
LASOFOXIFENE HCL Chemical Properties,Uses,Production
Uses
disintegrant, enteric coating, sustained release formulations
Biological Activity
lasofoxifene (tartrate) is a third-generation, nonsteroidal selective estrogen receptor modulator (serm).estrogen receptors are activated by the hormone estrogen (17β-estradiol). serms are characterized by having estrogen agonist action in some tissues while acting as estrogen antagonists in others [1][2].lasofoxifene, also known as cp 336,156, is a third-generation, nonsteroidal selective estrogen receptor modulator. lasofoxifene bound with high affinity to the human estrogen receptor-α with ic50 value of 1.5 nm [1]. lasofoxifene is also a cb2 inverse agonist [4].in aged female rats, lasofoxifene decreased total serum cholesterol and fat body mass, and no uterine hypertrophy was observed. in 5-month-old ovariectomized (ovx) sprague-dawley female rats, lasofoxifene completely prevented ovx-induced increases in body weight gain, total serum cholesterol, and serum osteocalcin. cp-336,156 completely prevented ovx-induced bone loss and inhibited the increased bone turnover associated with estrogen deficiency in lumbar vertebrae, proximal tibiae, and distal femora [1].in postmenopausal women with osteoporosis, lasofoxifene reduced risks of nonvertebral and vertebral fractures, er-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events [2][3].
Biochem/physiol Actions
Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
References
[1]. ke hz, paralkar vm, grasser wa, et al. effects of cp-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. endocrinology. 1998 apr;139(4):2068-76.
[2]. cummings sr, ensrud k, delmas pd, et al. lasofoxifene in postmenopausal women with osteoporosis. n engl j med. 2010 feb 25;362(8):686-96.
[3]. gennari l, merlotti d, nuti r. selective estrogen receptor modulator (serm) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. clin interv aging. 2010 feb 2;5:19-29.
[4]. kumar p, song zh. cb2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene. biochem biophys res commun. 2014 jan 3;443(1):144-9.
LASOFOXIFENE HCL Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Biochempartner | 0086-13720134139 | candy@biochempartner.com | CHINA | 967 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49390 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
| Dayang Chem (Hangzhou) Co.,Ltd. | 571-88938639 +8617705817739 | info@dycnchem.com | CHINA | 52867 | 58 |
| Henan Alfa Chemical Co., Ltd | +8618339805032 | alfa4@alfachem.cn | China | 12755 | 58 |
| Alfa Chemistry | +1-5166625404 | Info@alfa-chemistry.com | United States | 21317 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418684 +8618949823763 | sales@tnjchem.com | China | 25363 | 58 |
| Shanghai Innopharm Industrial Co., Ltd. | +86-21-59960785 +86-17701845089 | sales@hoyaopharm.com | China | 261 | 58 |
View Lastest Price from LASOFOXIFENE HCL manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2020-01-13 | LASOFOXIFENE HCL
190791-29-8
|
US $5.50 / KG | 1KG | 98%min | 1kg-100kg | Career Henan Chemical Co |
-
- LASOFOXIFENE HCL
190791-29-8
- US $5.50 / KG
- 98%min
- Career Henan Chemical Co